Company news
Ataibeckley Inc. (NASDAQ:ATAI) news
Every Ataibeckley Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI
July 17, 2026
AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder
July 6, 2026
AtaiBeckley to Join the Russell Indexes, Expanding Visibility Across U.S. Equity Markets
June 25, 2026
AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations
May 28, 2026
AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026
May 26, 2026
AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update
May 12, 2026
AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research
April 27, 2026
AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder
April 22, 2026
AtaiBeckley : to Participate in Upcoming Needham Healthcare Conferences
April 14, 2026
AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs
April 8, 2026
AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst
March 24, 2026
BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation
March 17, 2026
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day
March 9, 2026
AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update
March 5, 2026
AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression
March 2, 2026
AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder
February 25, 2026
AtaiBeckley To Host Virtual Investor Day on March 6, 2026
February 19, 2026
AtaiBeckley Appoints Michael Faerm as Chief Financial Officer
February 18, 2026
AtaiBeckley To Participate in Upcoming Investor Conferences
February 17, 2026
AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation
January 15, 2026
AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference
January 7, 2026
AtaiBeckley Completes Redomiciliation to the United States
December 30, 2025
AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)
December 23, 2025
AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio
December 10, 2025
Enhanced Fortifies Executive Leadership Team & Board of Directors
November 18, 2025
AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London
November 12, 2025
AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
November 11, 2025
AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression
November 9, 2025
atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health Therapies
November 4, 2025
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
October 19, 2025
atai Life Sciences Announces Proposed Public Offering of Common Shares
October 15, 2025
atai Life Sciences Announces Pricing of Public Offering of Common Shares
October 15, 2025
atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression
October 15, 2025
atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression
September 22, 2025
atai Life Sciences Awarded Grant from the National Institutes of Health
September 17, 2025
atai Life Sciences to Participate in September Investor Conferences
August 27, 2025
atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates
August 13, 2025
Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia
July 24, 2025
atai Life Sciences Announces $50 Million Private Placement Financing
June 30, 2025
atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression
June 30, 2025
atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies
June 1, 2025
atai Life Sciences to Participate in Upcoming Investor Conferences
May 28, 2025
atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression
May 19, 2025
atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates
May 13, 2025
atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder
May 12, 2025
atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
March 16, 2025
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
March 10, 2025
atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression
March 4, 2025
atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference
February 23, 2025
atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder
January 27, 2025